Pienta K J, Nguyen N M, Lehr J E
Meyer L. Prentis Comprehensive Cancer Center, Wayne State University School of Medicine, Michigan Cancer Foundation, Detroit 48202-0188.
Cancer Res. 1993 Jan 15;53(2):224-6.
N-4-Hydroxyphenylretinamide (fenretinide or 4HPR), a derivative of retinoic acid, has been demonstrated to decrease the development of prostate cancer in a rat carcinogenesis model. This study was undertaken to determine if 4HPR is an effective agent for the treatment of established prostate cancer. In vitro, 4HPR was cytotoxic to rat and human prostate cancer cells as well as endothelial cells. Utilizing three different angiogenesis inhibition assays, it was demonstrated that 4HPR inhibited angiogenesis as well as endothelial cell motility and tubule formation. In vivo, 4HPR inhibited prostate cancer growth in a significant manner. These findings suggest that 4HPR may be a potent inhibitor of early prostate cancer growth.
N-4-羟基苯基视黄酰胺（芬维A胺或4HPR），一种视黄酸衍生物，已在大鼠致癌模型中被证明可减少前列腺癌的发生。本研究旨在确定4HPR是否为治疗已确诊前列腺癌的有效药物。在体外，4HPR对大鼠和人类前列腺癌细胞以及内皮细胞具有细胞毒性。利用三种不同的血管生成抑制试验，证明4HPR可抑制血管生成以及内皮细胞迁移和小管形成。在体内，4HPR能显著抑制前列腺癌生长。这些发现表明，4HPR可能是早期前列腺癌生长的有效抑制剂。
